MKLP2-MITOSIS

MKlp2 - a mitotic kinesin and a prime target for cancer therapy

 Coordinatore INSTITUT CURIE 

 Organization address address: 26, rue d'Ulm
city: PARIS
postcode: 75248

contact info
Titolo: Mrs.
Nome: Corinne
Cognome: Cumin
Email: send email
Telefono: +33 1 56 24 66 20
Fax: +33 1 56 24 66 27

 Nazionalità Coordinatore France [FR]
 Totale costo 261˙384 €
 EC contributo 261˙384 €
 Programma FP7-PEOPLE
Specific programme "People" implementing the Seventh Framework Programme of the European Community for research, technological development and demonstration activities (2007 to 2013)
 Code Call FP7-PEOPLE-2012-IIF
 Funding Scheme MC-IIF
 Anno di inizio 2013
 Periodo (anno-mese-giorno) 2013-11-01   -   2015-10-31

 Partecipanti

# participant  country  role  EC contrib. [€] 
1    INSTITUT CURIE

 Organization address address: 26, rue d'Ulm
city: PARIS
postcode: 75248

contact info
Titolo: Mrs.
Nome: Corinne
Cognome: Cumin
Email: send email
Telefono: +33 1 56 24 66 20
Fax: +33 1 56 24 66 27

FR (PARIS) coordinator 261˙384.60

Mappa


 Word cloud

Esplora la "nuvola delle parole (Word Cloud) per avere un'idea di massima del progetto.

mklp    er    mad    shown    prime    motor    protein    interaction    addition    structure    anti    mitotic    functional    mitosis    cancer    characterization    mechanism    aim    structural    golgi    cytokinesis    kinesin    tumor    function    plk    domain    drugs   

 Obiettivo del progetto (Objective)

'Mklp2, a mitotic kinesin and a prime target for cancer therapy

MKlp2 belongs to kinesin 6 family and was first identified as an effector protein of small G protein Rab6A, involving in the retrograde transport between Golgi and ER. While its function in Golgi-ER trafficking awaits further study, MKlp2 has been shown to play crucial role in mitosis. It is essential to relocate chromosomal passenger protein Aurora B and the mitotic regulator Plk1 to the central spindle during anaphase. Depletion of MKlp2 results in failure of cytokinesis. In addition, MKlp2 is overexpressed in several human tumor cells and inhibition of MKlp2 reduces the tumor cell growth. Those properties make MKlp2 a prime target for developing anti cancer drugs. MKlp2 has been shown to interact directly to Plk1 and Mad2, the mitotic checkpoint complex protein. However, the mechanism of MKlp2 motor protein and how those interactions may regulate its function is unknown. In addition, MKlp2 possess unique sequences in its motor domain compared to other kinesins which may render its mechanism of nucleotide/microtubule binding. To understand how MKlp2 functions and how it’s regulated during mitosis, we propose a thorough functional and structural characterization of this interesting motor protein.

Aim1. Functional and structural characterization of the motor domain of MKlp2, the kinesin involves in cytokinesis and a potential target for anti-cancer drugs Aim2. To study in detail the interaction between MKlp2 and Plk1, its regulation of the function of MKlp2, and to determine the structure of the complex Aim3. To characterize the interaction between MKlp2 tail domain and Mad2, the structure of the complex, and the role of the interaction in cytokinesis

Our results from this multidisciplinary proposal will provide valuable information on the mechanism of MKlp2, further our understanding on kinesin motors, and allow development of anti-cancer drugs.'

Altri progetti dello stesso programma (FP7-PEOPLE)

PROTFLEXPRED (2008)

Prediction of protein flexibility and its role in protein-protein interactions and binding specificity

Read More  

LIGHTHALOS (2012)

Crowns of neutrons: reactions and decays to penetrate the halos of Be-14 and He-8

Read More  

QUEST (2009)

Quantitative Estimation of Earth's Seismic Sources and Structure

Read More